
Marker Therapeutics fell 21.7% from $1.09 to $0.85, behind the S&P 500's +10.2%. Its worst day was Nov 5 (−11.3%), and its low came Nov 16 at $0.83.
Nov 19, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Marker Therapeutics closed at its highest level of the year, 100.9% above where the year started.
+17.7% · S&P 500 −0.3%
Marker Therapeutics shares rose 17.1%, while the S&P 500 fell 2.0%.
+17.1% · S&P 500 −2.0%
Story events cover the past 12 months · Times ET
EPS of $-0.09 beat the $-0.19 estimate on $1.1M revenue (est. $649,200.00).
−1.5% · S&P 500 −0.5%
Marker Therapeutics shares rose 19.9%, while the S&P 500 rose 0.6%.
+19.9%, the year's best day · S&P 500 +0.6%
EPS of $-0.16 beat the $-0.19 estimate on $0.00 revenue (est. $665,600.00).
−2.1% · S&P 500 −0.1%
Marker Therapeutics shares rose 13.5%, while the S&P 500 fell 0.5%.
+13.5% · S&P 500 −0.5%
EPS of $-0.09 beat the $-0.19 estimate on $0.00 revenue (est. $665,600.00).
+1.8% · S&P 500 −0.5%
Marker Therapeutics shares rose 15.4%, while the S&P 500 rose 0.4%.
+15.4% · S&P 500 +0.4%
EPS of $-0.10 beat the $-0.14 estimate on $0.00 revenue (est. $2.2M).
+1.0% · S&P 500 −1.0%
Where it ended: a close of $0.85 on Nov 18, 2026. Up next: Q4 2026 earnings on Mar 17, 2027 (EPS est. $-0.19, revenue est. $712,264.00).
Nothing in the past 12 months.
All MRKR dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MRKR and SPY from Benzinga historical bars. Not investment advice.